ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab.

Doris P Molina-Henry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.